Abecma’s mechanism of action. Abecma is a first-in-class genetically modified autologous CAR-positive T-cell therapy directed to B-cell maturation antigen (BCMA), a protein expressed on the malignant ...

At median follow-up of more than 30 months, Abecma maintained a 51% reduction in risk of disease progression or death with median PFS of 13.8 months compared with 4.4 months for standard regimens ...

Abecma more than tripled progression-free survival (13.3 months vs. 4.4 months) compared with standard regimens for triple-class exposed multiple myeloma. Safety results were consistent with the ...

Abecma is used to treat multiple myeloma in adults in certain situations. Specifically, it’s used to treat multiple myeloma that either: has returned after it was treated successfully before, or ...

Bristol Myers Squibb (BMS) received U.S. Food and Drug Administration (FDA) approval for label updates for its CAR T cell ...

Restricted availability under an FDA-mandated drug safety program has limited the reach of CAR-T cell therapies for certain ...

Abecma is the first and only CAR T cell therapy to demonstrate superiority over standard regimens in triple-class exposed relapsed and refractory multiple myeloma in a randomized, controlled Phase ...

ABECMA INTERACTION WITH CANNABIS OR CBD. Cannabis (often called marijuana) and cannabis products, such as cannabidiol (CBD), have not been specifically reported to interact with Abecma.

Overview: Abecma is used to treat a certain blood cancer. Common side effects include fever, tiredness, and nausea. Get emergency help if you have trouble breathing, fever of more than 100.4 F (38 ...

Abecma generated U.S. revenue of $242 million in 2024, within 2seventy’s earlier-issued guidance to investors of between $240 million and $250 million.

Summary. 2seventy bio, Inc. focuses on Abecma, an FDA-approved CAR T cell therapy for multiple myeloma. TSVT's strategic realignment includes selling non-core assets to Regeneron and Novo Nordisk.